(lp0
S'The Rigel Pharmaceuticals, Inc.  Given Average Rating of Buy by Analysts Petro Global News 24 - Jan 31, 2017 RIGL has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded shares of Rigel Pharmaceuticals from a hold rating to a buy rating and set a $2.75 price target on the stock in a research note on Tuesday, December 6th.'
p1
aS"Why Rigel Pharmaceuticals, Inc. Got Hammered Today Motley Fool - Oct 20, 2016 Rigel Pharmaceuticals  is down 23% at 11:30 a.m. EDT after the company reported a second phase 3 clinical trial testing for its spleen tyrosine kinase inhibitor, fostamatinib, in patients with adult chronic/persistent immune ...Rigel Announces Results from the Second FIT Phase 3 Study and the Long-Term ... - PR Newswire Stock Update : Here's Why Rigel Pharmaceuticals, Inc. Shares Are ... - Smarter Analyst"
p2
aS'Rigel Pharmaceuticals Is Worth A Timely Look Seeking Alpha - Mar 27, 2017 Rigel Pharmaceuticals  is pursuing a novel mechanism of action with its drug, fostamatinib. Spleen Tyrosine Kinase  inhibitors have shown positive results in studies analyzing allergies, autoimmune diseases, and immune cell&nbsp;...Rigel Pharmaceuticals Inc.  Soars 9.58% on March 27 - Equities.comWill Rigel Pharmaceuticals  Continue to Surge Higher? - Yahoo Finance'
p3
aS"Here's Why Rigel Pharmaceuticals, Inc. is Skyrocketing Today Motley Fool - Aug 30, 2016 What: Shareholders of Rigel Pharmaceuticals , a small-cap clinical stage biopharma, are having a pleasant Tuesday.Why Rigel Pharma Is Making a Run - 24/7 Wall St.Rigel Announces Press Release and Conference Call Schedule on Tuesday, August ... - PR Newswire "
p4
aS"Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing ... PR Newswire  - Jan 16, 2017 SOUTH SAN FRANCISCO, Calif., Jan. 16, 2017 /PRNewswire/ -- Rigel Pharmaceuticals  today announced that on January 3, 2017 and January 16, 2017 the Compensation Committee of Rigel's Board of Directors approved the grant of&nbsp;..."
p5
aS'Why You Should Own Rigel Pharmaceuticals, Inc. Seeking Alpha - Jul 18, 2016 Rigel Pharmaceuticals Inc.  is a clinical stage biotech company with a market cap of approximately $200 million.'
p6
aS"Why this Peninsula biotech's layoffs aren't necessarily a bad thing (except ... San Francisco Business Times  - Sep 16, 2016 A South San Francisco company with positive results last month from a clinical trial now says it will lay off nearly four in 10 employees and part ways with its co-founder.Rigel Restructures to Focus on Fostamatinib Commercialization - PR Newswire "
p7
aS'Rigel: Upcoming NDA Submission Presents Buying Opportunity Seeking Alpha - Mar 23, 2017 Rigel Pharmaceuticals  has an SYK inhibitor named fostamatinib which is in Phase 3 trials for chronic immune thrombocytopenic purpura .'
p8
aS'Fostamatinib Study Results Continue to Trend Positive PR Newswire  - Jan 30, 2017 30, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.  today announced updates from the clinical program of fostamatinib in patients with chronic immune thrombocytopenic purpura .Rigel Pharmaceuticals  Stock: NDA Coming Soon! - CNA Finance Premarket Biotech Movers: Ironwood Pharmaceuticals, Rigel Pharmaceuticals ... - TheStreet.com'
p9
aS"Rigel Pharmaceuticals Inc: Hits 4-month high Times of India - Mar 8, 2017 ... ** Drug developer's shares rise as much as 14.2 pct to $2.98 - their highest intraday level since mid-November. ** Rigel on Tuesday indicates it is on track to submit a U.S. marketing application in Q1 for its experimental drug fostamatinib to ..."
p10
a.